The role of immune checkpoint inhibition (ICI) in the treatment of prostate cancer (PC) still remains elusive. It has been proposed that combination of ICI with other molecules increases the efficacy of immunotherapy in PC.
To systematically review the literature to assess the potential role of ICI in combination with additional therapies for the management of metastatic castration-resistant PC (mCRPC).
A systematic review using Medline and scientific meeting records was carried out in September 2020 according to the Preferred Reporting Items for Systematic Review and Meta-analyses guidelines. Ongoing trials of immunotherapy with standard mCRPC therapeutics were identified via a systematic search on ClinicalTrials.gov.
A total of five full-text papers, ten congress abstracts, and 15 trials on ClinicalTrials.gov were identified. Preclinical evidence suggests that combinational approaches might be considered to enhance the efficacy of ICI in PC patients. This led to the design of more than 50 immunotherapy-based clinical trials. The majority of the studies focus on ICI combinations with vaccines, androgen deprivation therapy, chemotherapy, PARP inhibition, radiotherapy, and prostate-specific membrane antigen-guided radioligand therapy. Preliminary analyses reported promising findings for the use of ICI in combination with other anticancer therapies. However, no phase 3 trial has yet reported final results, so no level 1 evidence with long-term outcomes currently supports the combination of ICI with mCRPC therapies.
Preclinical and clinical trials have demonstrated that combining immunotherapy with standard mCRPC treatment options has the potential to provide a synergistic effect. Nonetheless, a better understanding of the mechanism and of the optimal treatment approach is still needed.
We reviewed the literature on immunotherapy in combination with standard treatments for patients with metastatic castration-resistant prostate cancer (mCRPC). Current evidence supports the hypothesis that immunotherapeutic drugs might be effective in mCRPC if combined with other treatment options. However, results of ongoing trials are still awaited before this novel treatment approach can be implemented in the daily practice.
European urology oncology. 2020 Nov 23 [Epub ahead of print]
Isabel Heidegger, Andrea Necchi, Andreas Pircher, Igor Tsaur, Giancarlo Marra, Veeru Kasivisvanathan, Alexander Kretschmer, Romain Mathieu, Francesco Ceci, Roderick C N van den Bergh, Constance Thibault, Derya Tilki, Massimo Valerio, Christian Surcel, Giorgio Gandaglia, EAU-YAU Prostate Cancer Working Party
Department of Urology, Medical University Innsbruck, Innsbruck, Austria. Electronic address: ., Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Department of Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, Innsbruck, Austria., Department of Urology and Pediatric Urology, Mainz University Medicine, Mainz, Germany., Department of Urology, San Giovanni Battista Hospital, University of Turin, Turin, Italy., Division of Surgery and Interventional Science, University College London, London, UK., Department of Urology, Ludwig-Maximilians-University of Munich, Munich, Germany., Department of Urology, CHU Rennes, Rennes, France., Department of Nuclear Medicine, San Giovanni Battista Hospital, Turin, Italy., Department of Urology, Antonius Hospital, Utrecht, The Netherlands., Department of Oncology, Hôpital Européen Georges Pompidou, Paris, France., Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany., Department of Urology, CHUV Lausanne, Lausanne, Switzerland., Center of Urologic Surgery, Dialysis and Renal Transplantation, Fundeni Clinical Institute, Bucharest, Romania., Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.